NCT01736436 - APG101 in Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Treatment with APG101

Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly

PROCEDURE

Bone marrow collection

During the study, bone marrow will be collected 4 times to assess study objectives

PROCEDURE

Blood drawings

During the study, blood will be drawn at different time points to assess study objectives

Trial Locations (2)

Universitaetsmedizin Mannheim, III. Medizinische Klinik, Haematologie und Onkologie, Mannheim

Universitaetsklinik Heidelberg, Medizinische Klinik V, Haematologie, Onkologie & Rheumatologie, Heidelberg